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Malignant pleural mesothelioma (MPM) is an aggressive malig-
nancy associated with exposure to asbestos, with poor prognosis
and no effective therapies. The strong inhibitory activities of growth
hormone-releasing hormone (GHRH) antagonists have been dem-
onstrated in different experimental human cancers, including lung
cancer; however, their role in MPM remains unknown. We assessed
the effects of the GHRH antagonists MIA-602 and MIA-690 in vitro
in MPM cell lines and in primary MPM cells, and in vivo in MPM
xenografts. GHRH, GHRH receptor, and its main splice variant SV1
were found in all the MPM cell types examined. In vitro, MIA-602
and MIA-690 reduced survival and proliferation in both MPM cell
lines and primary cells and showed synergistic inhibitory activity
with the chemotherapy drug pemetrexed. In MPM cells, GHRH
antagonists also regulated activity and expression of apoptotic
molecules, inhibited cell migration, and reduced the expression of
matrix metalloproteinases. These effects were accompanied by
impairment of mitochondrial activity and increased production of
reactive oxygen species. In vivo, s.c. administration of MIA-602 and
MIA-690 at the dose of 5 μg/d for 4 wk strongly inhibited the
growth of MPM xenografts in mice, along with reduction of tumor
insulin-like growth factor-I and vascular endothelial growth factor.
Overall, these results suggest that treatment with GHRH antag-
onists, alone or in association with chemotherapy, may offer an
approach for the treatment of MPM.
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Malignant pleural mesothelioma (MPM) is a rare and ag-gressive cancer affecting the pleura (typically associated
with exposure to asbestos), with poor prognosis and a median
survival ranging from 3 to 12 mo. The incidence of MPM is
expected to increase in the next decades because of the long
latency from time of asbestos exposure to development of the
disease (1). There is no effective treatment for MPM and since
surgery is controversial, often a multimodal approach is applied
that includes chemotherapy and sometimes radiotherapy, even at
early stages. The first-line option for inoperable MPM is che-
motherapy with cisplatin and pemetrexed (PEM); however, this
is mainly palliative and has a short and insufficient efficacy (1, 2).
Therefore, new therapeutic strategies are urgently needed. Path-
ologically, MPM comprises three main histologic types: epitheli-
oid, sarcomatoid, and biphasic, which has both epithelioid and
sarcomatoid components (3). The pathogenesis of MPM is mul-
tifactorial. Inhaled asbestos fibers migrate to the pleural space,
causing DNA damage and abnormal repair of mesothelial cells,
acute inflammation with the release of inflammatory cytokines,
recruitment of macrophages and neutrophils, activation of various
kinases, an increase in expression of protooncogenes, and pro-
liferation of airway epithelial cells (4).
Growth hormone-releasing hormone (GHRH) is a neuro-
peptide produced in the hypothalamus. In the anterior pituitary,
GHRH regulates the synthesis and secretion of growth hormone
(GH) and the proliferation of pituitary cells, by binding to pituitary
type GHRH receptor (pGHRH-R) (5). GHRH also exerts direct
activities in extrapituitary cells and tissues (6, 7), which include,
among others, cardioprotection (8, 9), regeneration of pancreatic
islets (10), wound healing (11), and survival and antiapoptotic ef-
fects (12, 13). Moreover, GHRH functions as an autocrine/para-
crine growth factor in nonmalignant cells and in tumors through
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mechanisms mediated by GHRH-R and its splice variant type 1
(SV1) (5, 6, 14). The stimulatory loop, formed by tumor-derived
GHRH and its receptors, can be blocked by GHRH antagonists,
resulting in inhibition of tumor growth in experimental models. In
fact, GHRH antagonists suppress in vitro and in vivo the pro-
liferation of many experimental human cancers, including lung
cancer (14–17).
Recently, new GHRH antagonists of the Miami (MIA) series
have been synthetized, such as MIA-602 and MIA-690, with
greatly increased anticancer activity, higher binding affinity, and
low endocrine effect on the GH/insulin-like growth factor I
(IGF-I) axis. These analogs display potent inhibitory actions in
thyroid, lung, gastric, renal, prostate, and endometrial cancer, as
well as in glioblastoma, colorectal adenocarcinoma, lymphoma,
and retinoblastoma (16–25). To date, however, the role of
GHRH antagonists in MPM remains to be determined.
In this study, we evaluated the potential inhibitory activities of
MIA-602 and MIA-690 on the survival and proliferation of hu-
man MPM cell lines and primary MPM cells. The effects on
apoptosis and cell migration, along with mitochondria metabo-
lism, were also analyzed in MPM cell lines. Finally, the antitumor
activities of GHRH antagonists were assessed in vivo, in mice
xenografted with human MPM cells.
Results
Expression of pGHRH-R, SV1, and GHRH in MPM Cells. Results from
Western blot analysis showed that both pGHRH-R and SV1 as
well as GHRH proteins are expressed in pleural mesothelial cells
(MeT-5A) and in pleural biphasic and epithelioid MPM cell lines
(MSTO-211H and REN, respectively) (Fig. 1).
GHRH Antagonists Inhibit Cell Survival and Proliferation, Promoting
Apoptosis in MPM Cell Lines. The inhibitory efficacy of MIA-602
and MIA-690 was initially determined in human MPM cell lines
treated with the antagonists for 24 h at concentrations of 1 to
2,000 nM. We found a similar dose-dependent reduction in sur-
vival and proliferation of MSTO-211H and REN cells with both
MIA-602 (SI Appendix, Fig. S1 A–D) and MIA-690 (SI Appendix,
Fig. S1 E–H), particularly from 50 to 2,000 nM, compared with
controls (IC50 for MIA-602: 3,925 nM in MSTO-211H and
2,350 nM in REN; IC50 for MIA-690: 2,779 nM in MSTO-211H
and 2,431 nM in REN). Likewise, in cells treated for 48 h, the
effect was observed from 50 nM for survival (SI Appendix, Fig. S2
A–D) and from 100 nM for proliferation (SI Appendix, Fig. S2 E–
H) in both cell lines. Interestingly, in MeT-5A pleural mesothelial
cells, both antagonists reduced survival only at the highest con-
centrations (SI Appendix, Fig. S3 A and B), while having no effect
on proliferation (SI Appendix, Fig. S3 C and D). Because of the
striking decrease with both antagonists in cell survival at 1,000 nM
(1 μM) (MIA-602: 23% and MIA-690: 27.4% for MSTO-211H;
MIA-602: 31.54% and MIA-690: 32.2% for REN) and pro-
liferation (MIA-602: 23.63% and MIA-690: 24.93% for MSTO-
211H; MIA-602: 25.59% and MIA-690: 27.34% for REN), 1 μM
was chosen as concentration for subsequent studies.
We next examined the possible combinatory cytotoxic activity
produced by MIA-602 or MIA-690 with the anticancer drug PEM.
MPM cells were treated for 72 h with each antagonist at 1 μM and
with PEM at 10 or 50 nM in MSTO-211H cells or at 50 or 100 nM
in REN cells, which are less sensitive to the cytotoxic effect of the
drug. MIA-602 (Fig. 2 A–D) and MIA-690 (SI Appendix, Fig. S1 I–
L) were synergistic in inhibiting cell survival in both MPM cell lines,
with Combination Index (CI) values <1 at all of the concentrations
of PEM tested. The proapoptotic effect of the antagonists was
assessed at 12, 24, and 48 h in the MPM cell lines. MIA-602 and
MIA-690 increased the activity of proapoptotic caspase-3 (Fig. 2 E
andG) at 24 h in both MPM cell lines. Moreover, expression of the
antiapoptotic protein Bcl-2 was reduced by MIA-602 in both MPM
cell lines at 24 and 48 h (Fig. 2 F andH) and by MIA-690 at 48 h in
MSTO-211H cells (SI Appendix, Fig. S1M) and at 12, 24, and 48 h
in REN cells (SI Appendix, Fig. S1P). Accordingly, in both MPM
cell lines, the tumor suppressor protein p53 was up-regulated by the
antagonists at 48 h (Fig. 2 I and K and SI Appendix, Fig. S1 N and
Q), whereas oncogenic c-Myc was reduced at 24 and 48 h (Fig. 2 J
and L and SI Appendix, Fig. S1 O and R).
GHRH Antagonists Inhibit Growth and Migration of MPM Cell Lines.
To further assess whether GHRH antagonists suppress the
growth of MPM cells, we performed colony formation assay. Our
data indicated a similar reduction in the ability to form colonies
after 10 d in both MSTO-211H and REN cells treated with MIA-
602 (Fig. 3 A and B) and MIA-690 (SI Appendix, Fig. S4 A and B),
compared with untreated cells. The ability of MPM cells to migrate
and invade the pleura is a major characteristic of tumor growth (4);
thus, we next assessed cell migration by wound-healing assay. MIA-
602 and MIA-690 strongly inhibited the wound closure in both
MPM cell lines to a similar extent. In REN cells, the effect was
detected at 1 μM and was even increased at 2 μM for both an-
tagonists (Fig. 3C and SI Appendix, Fig. S4C). In MSTO-211H cells,
only 1 μM was effective for both antagonists (SI Appendix, Fig.
S4D). Moreover, in both cell lines, MIA-602 and MIA-690 equally
reduced the mRNA levels of molecules implicated in cell migration
and tumor growth [i.e., metalloproteinase (MMP)-2 and MMP-9]
(Fig. 3 D and E and SI Appendix, Fig. S4 E and F).
MIA-602 and MIA-690 Induce Mitochondrial Damage. Since mito-
chondria are central players in apoptosis (26), and we show here
that GHRH antagonists promote apoptosis in MPM cells, we
evaluated the role of mitochondria in the antitumor effects of MIA-
602 and MIA-690. Mitochondrial membrane potential (ΔΨm), an
indicator of mitochondrial activity, was dramatically reduced in
MSTO-211H and REN cells treated with the antagonists for 48 h,
as measured by flow cytometry analysis of the mitochondria-
sensitive dye JC-1 (SI Appendix, Fig. S5 A and D). This result was
accompanied by elevation of reactive oxygen species (ROS) (SI
Appendix, Fig. S5 B and E), which causes impairment of ΔΨm,
release of mitochondrial proteins, and activation of caspase cas-
cades (27). Moreover, MIA-690, but not MIA-602, blunted the
expression of superoxide dismutase 2 (SOD-2), a key mitochondrial
antioxidant enzyme (SI Appendix, Fig. S5 C and F).
GHRH Antagonists Inhibit Cell Survival and Proliferation in Human
Primary MPM Cells. To next determine the effects of MIA-602
and MIA-690 in MPM cells obtained from pleural biopsy tissues
of patients with MPM, we first analyzed the presence of GHRH-
R and GHRH in biphasic, epithelioid, and sarcomatoid cells.
Western blot and RT-PCR analysis showed expression of both
+
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Fig. 1. Protein expression for pGHRH-R (Upper), SV1 (Middle), and GHRH
(Lower) in MeT-5A pleural mesothelial cells, and in MSTO-211H (MSTO) and
REN human MPM cell lines, assessed by Western blot. LNCaP prostate cancer
cells were used as positive control (+) for pGHRH-R and SV1, MCF-7 breast
cancer cells were used as positive control for GHRH, and actin served as in-
ternal control.
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GHRH-R and GHRH protein (Fig. 4 A and B) and mRNA (SI
Appendix, Fig. S6 A and B) in all MPM types that were also
positive for SV1 mRNA (SI Appendix, Fig. S6A). MIA-602 and
MIA-690 displayed similar dose-dependent inhibitory activity on
survival and proliferation in biphasic (Fig. 4 C and D and SI
Appendix, Fig. S6 C and D), epithelioid (Fig. 4 E and F and SI
Appendix, Fig. S6 E and F), and sarcomatoid cells (Fig. 4 G and
H and SI Appendix, Fig. S6 G and H). MIA-602 was slightly more
effective than MIA-690, being significant from 1 nM on survival,
and from 50 nM on proliferation of epithelioid (Fig. 4 E and F)
and sarcomatoid cells (Fig. 4 G and H). MIA-690, in turn, was
more effective than MIA-602 in biphasic cells, starting from
1 nM for survival (SI Appendix, Fig. S6C) and from 100 nM for
proliferation (SI Appendix, Fig. S6D).
GHRH Antagonists Inhibit the Growth of MPM in Vivo. The thera-
peutic potential of MIA-602 and MIA-690 was evaluated in
NOD/SCID/gamma chain−/− mice xenografted with MSTO-211H
cells. When the tumors became palpable, mice were randomly
assigned to receive a daily s.c. injection of MIA-602 or MIA-690
(5 μg/d) or vehicle for 4 wk. Both antagonists showed a remark-
able inhibitory effect on tumor growth, as demonstrated by the
reduction in tumor volume and weight (Fig. 5 A and B, P < 0.001).
Moreover, in xenografts, the antagonists reduced the production
of IGF-I protein (Fig. 5C) and blunted mRNA levels of VEGF
(Fig. 5D). Histopathological examination of the tumors showed
a uniform growth of neoplastic cells, morphologically consistent
with biphasic MPM. More- or less-extensive areas of necrosis were
observed in all cases, with a slight increase in treated animals
(mean values 35% and 36% for treatments with MIA-602 and
MIA-690, respectively, compared with 29% of untreated xeno-
grafts) (SI Appendix, Fig. S7).
Discussion
MPM is an aggressive tumor with poor prognosis due to the un-
availability of effective therapies. Even thoughMPM is a rare cancer,
its incidence is expected to increase in the next two decades because
of the worldwide exposure to asbestos over the past years (1).
MIA-602 and MIA-690 are part of the latest MIA series of
GHRH antagonists with potent antitumor activity in different can-
cers, including lung cancer (16–25); however, their inhibitory effects
in MPM remain to be investigated. This study shows that MIA-602
and MIA-690 can potently—and to a similar extent—inhibit the
growth of human MPM cell lines and primary MPM cells in vitro
and display antitumor effects in vivo in MPM xenografts.
GHRH-R and its splice variant SV1 have been implicated in
the antitumor effects of GHRH antagonists (6, 14, 15). Impor-
tantly, the expression of nonhypothalamic GHRH, pGHRH-R,
and SV1 has been demonstrated in different tumors and cancer
cell lines, suggesting that locally produced GHRH might func-
tion as an autocrine/paracrine growth factor in various cancers.
Interestingly, cancer cells transfected with SV1 exhibited in-
creased cell proliferation, suggesting that blockade of ligand-
independent activity of SV1 would lead to the development of
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Fig. 2. Inhibitory effects of GHRH antagonists in MPM cells. Cell survival (A and C) and proliferation (B and D) assessed by MTT and BrdU assays, respectively,
in MSTO-211H and REN cells untreated or treated for 72 h in medium with 2.5% serum (c, control medium) with 1 μM MIA-602, alone or with PEM, at the
concentrations indicated. Results, expressed as percent of control, are mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. c; #P < 0.05, ##P < 0.01; n = 4.
Caspase-3 activity in MSTO-211H (E) and REN cells (G) treated for 24 h with 1 μM MIA-602 or MIA-690. Results, expressed as percent of control are mean ±
SEM. *P < 0.05 and **P < 0.01 vs. control; n = 3. Representative Western blot for Bcl-2 (F and H), p53 (I and K), and c-Myc (J and L) in cells treated with 1 μM
MIA-602 or MIA-690 for the indicated times. Results, normalized to actin and expressed as percent of control (Time 0), are mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001; n = 3. ns, not significant.
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anticancer therapies (28). Here, we demonstrate the presence of
pGHRH-R, SV1 and GHRH in MPM cell lines and primary
MPM cells, underpinning the potential inhibitory activities of
GHRH antagonists in MPM.
The MPM cell lines examined in this study included epithelioid
cells (the most common and with best prognosis for MPM patients)
and biphasic cells (a mixture of epithelioid and sarcomatoid cells
and with a prognosis depending on the percentage of the epithe-
lioid component) (3). Primary epithelioid, sarcomatoid (with worst
prognosis), and biphasic MPM cells were also analyzed. MIA-602
and MIA-690 similarly inhibited survival and proliferation in all of
the cell types tested, indicating anticancer properties in the least-
aggressive as well as the most-aggressive phenotypes. These effects
were significant at both 24 and 48 h, even at very low concentra-
tions, and were comparable with those previously observed for
antagonists of MIA series in other cancer cells (16, 18–21).
Conversely, GHRH antagonists showed no effect in MeT-5A
mesothelial cells, which expressed pGHRH-R, SV1, and GHRH.
It is tempting to speculate that these cells, being nonmalignant,
have a reduced autocrine/paracrine stimulatory loop produced
by GHRH and/or IGF-I/II and are likely expressing lower levels
of SV1 compared with MPM cells. Although attractive, these
hypotheses require further investigation.
In addition to the inhibitory effects per se, GHRH antagonists
acted synergistically with PEM to reduce MPM cell survival, sug-
gesting the ability to sensitize the cells to chemotherapy-induced
toxicity. Several factors may contribute to this synergism, including
induction of proapoptotic signaling and inhibition of oncogenic and
antiapoptotic molecules by GHRH antagonists. Moreover, differ-
ent survival pathways are involved in resistance to chemotherapy in
MPM, including PI3K/Akt, a downstream component of IGF-I
receptor and a major antiapoptotic pathway and frequently over-
expressed in cancer cells (29). Herein, MIA-602 and MIA-690
down-regulated IGF-I in MPM xenografts, providing, at least in
part, a mechanistic explanation for the inhibitory effect on tumor
growth. Thus, it will also be important to explore the role of Akt
and its downstream effector proteins in the antitumor activities of
GHRH antagonists in MPM. In fact, the mechanisms of action
of GHRH antagonists in various cancers have been the subject of
intense investigations (16, 19, 23, 30). Along with the endocrine
effects on the GH/IGF-I axis, direct mechanisms include blockade
of the autocrine/paracrine activity of GHRH and IGF-I/II pro-
duction in tumors (14, 15). Suppression of tumor growth factors,
like VEGF, has also been reported (24, 31, 32). Other emerging
mechanisms comprise the up-regulation of molecules involved in
cell cycle arrest and apoptosis, such as p53 and caspases, and the
inhibition of oncogenic and antiapoptotic pathways like c-Myc and
Bcl-2 (20, 25, 31, 33, 34). Accordingly, in MPM cells, MIA-602 and
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Fig. 4. Inhibitory effects of MIA-602 in primary MPM cells. Representative
Western blot of GHRH-R (A) and GHRH protein (B) in biphasic (Biph), epi-
thelioid (Epit), and sarcomatoid (Sarc) MPM cells. LNCaP prostate cancer cells
and MCF-7 breast cancer cells were used as positive control (+) for GHRH-R
and GHRH, respectively. Cell survival (MTT assay) and proliferation (BrdU
assay) in biphasic (C and D), epithelioid (E and F), and sarcomatoid (G and H)
cells cultured in either normal medium (NM) or serum-deprived medium (c,
control) for 12 h, and then treated for 24 h with MIA-602 at the concen-
trations indicated. Results, expressed as percent of control, are mean ± SEM.
*P < 0.05, **P < 0.01, and ***P < 0.001 vs. c; n = 3. ns, not significant.
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MIA-690 elevated p53 and reduced c-Myc levels, strongly increased
caspase-3 activity, and inhibited Bcl-2 expression. Notably, p53 is
mutated in ∼15% of MPMs, with hyperactivation of survival and
antiapoptotic pathways and resistance to chemotherapy. Expression
and activity of p53, in turn, can be dramatically increased by DNA
damage, leading to cell cycle arrest, apoptosis, and inhibition of
VEGF, which is highly expressed in MPM and implicated in tumor
growth and angiogenesis (4, 31, 35, 36). It has been also shown that
inhibition of c-Myc promotes apoptosis and sensitizes MPM cells to
cytotoxicity by kinase inhibitors (37). Moreover, in line with recent
findings (20, 25), MIA-602 and MIA-690 in the present study
strongly inhibited cell motility and invasion of MPM cells and
blunted the expression of MMP-2 and MMP-9, key regulators of
tumor growth, metastasis, and angiogenesis (38).
It has been demonstrated that GHRH and its agonistic ana-
logs, like MR-409 and MR-356, display extrapituitary activities,
including cardioprotection, an increase in survival of pancreatic
islets after transplantation, and acceleration of wound healing,
suggesting their potential clinical use in the fields of cardiology,
diabetes, and others (5–11, 13). GHRH, however, also functions
as a stimulatory growth factor in cancer cells, thus raising serious
concerns for its therapeutic use (14, 28, 31). Importantly, Schally
et al. (39) recently reported that in vivo, MR-409 suppresses the
growth of different human experimental cancers to an extent and
at doses comparable to those observed for the antagonists MIA-
602 and MIA-690. These effects were paralleled by the down-
regulation of GHRH-R in pituitary and tumors and the re-
duction in serum levels of IGF-I. In line with these findings, a
different study showed that MR-356 inhibited experimental
stomach cancer in vivo and reduced serum IGF-I (40). Thus,
along with the antineoplastic effects of GHRH antagonists, the
abovementioned findings may provide indications for the broad
therapeutic use of these agents and alleviate the concerns on
tumor growth.
Bcl-2 family members are essential regulators of ΔΨm by
maintaining the integrity of the mitochondrial outer membrane,
whereas proapoptotic molecules disrupt the mitochondrial mem-
brane with release of apoptotic factors (26). Here, both MIA-602
and MIA-690 caused a loss/alteration of ΔΨm, in line with the
observed down-regulation of Bcl-2 and increase in p53 expression
and caspase-3 activity. GHRH antagonists also elevated ROS
production, which has been related to mitochondrial dysfunction
and apoptosis in MPM (27, 41). Moreover, MIA-690, but not
MIA-602, reduced the mRNA levels of SOD-2, encoding for a
mitochondrial enzyme with antiapoptotic functions against oxi-
dative stress (27). The involvement of mitochondria in the in-
hibitory activities of GHRH antagonists has been previously
described, in line with our findings (42, 43). Interestingly, the
results on the synergistic effect of GHRH antagonists and PEM
are consistent with the apoptotic activity of PEM, which has been
associated with mitochondrial dysfunction and generation of
ROS (41).
The antitumor activities of MIA-602 and MIA-690 were fur-
ther confirmed in primary cells from pleural biopsy tissues of
patients with MPM, in which GHRH comparable inhibitory effects
were observed in epithelioid, sarcomatoid, and biphasic cell types.
Furthermore, in vivo, MIA-602 and MIA-690 strongly reduced
tumor volume and weight in mice xenografted with MPM cells.
Interestingly, GHRH antagonists reduced tumor IGF-I levels in
these mice, suggesting that autocrine/paracrine mechanisms are
implicated in suppression of tumor growth. Moreover, recent
in vivo studies demonstrated that in the prostate, GHRH antag-
onists suppress IGF-I signaling, which can be ligand-independently
activated by tumor-derived GHRH (25). Importantly, alterations
in IGF-system components have been reported in MPM, sug-
gesting implication in tumorigenesis (44). That VEGF expression
is reduced in xenografts further strengthens the antitumor and
antiangiogenic role of MIA-602 and MIA-690 in MPM, in agree-
ment with studies in other cancer cell models, including non-small
cell lung cancer (24, 32).
In conclusion, our results demonstrate in vitro and in vivo, the
antitumor activity of MIA-602 and MIA-690 in MPM, suggesting
that GHRH antagonists could be considered for use in future
therapeutic strategies, alone or in combination with standard
therapies.
Methods
Please see SI Appendix, Materials and Methods for more information.
Cell Lines and Reagents. The MSTO-211H (human biphasic MPM) cell line and
MeT-5A (human mesothelium) cells were obtained from the American Type
Culture Collection and cultured following the manufacturer’s instructions.
The REN (human epithelioid MPM) cell line was kindly provided by Giorgio
Scagliotti, Department of Oncology, University of Turin, Orbassano, Italy and
cultured as described previously (45). GHRH-R antagonists MIA-602 ([(PhAc-
Ada)0-Tyr1, D-Arg2, Fpa56, Ala8, Har9, Tyr(Me)10, His11, Orn12, Abu15, His20,
Orn21, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2) and MIA-690 ([(PhAc-Ada)
0
-Tyr1, D-Arg2, Cpa6, Ala8, Har9, Fpa510, His11, Orn12, Abu15, His20, Orn21, Nle27,
D-Arg28, Har29]hGH-RH(1-29)NH2) were synthesized and purified in the A.V.S.
laboratory as described previously (18).
Human Primary MPM Cells. Human primary biphasic, epithelioid, and sarco-
matoid MPM cells were isolated after diagnostic thoracoscopies of MPM
patients and cultured as described previously (46). The study was approved
by the ethical committees of the Biological Bank of Mesothelioma, the S.S.
Antonio e Biagio General Hospital (Alessandria, Italy), and the San Luigi
Gonzaga Hospital (Orbassano, Italy) (studies: #9/11/2011; #126/2016). MPM
patients gave their informed consent for the use of primary cells obtained
from thoracoscopies.
Cell Survival and Proliferation. Cell survival and proliferation were assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
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Fig. 5. Inhibitory effects of GHRH antagonists on the growth of MPM in vivo.
(A) Representative MSTO-211H tumors, excised at the end of the experiments,
frommice s.c. injected for 4 wk with either vehicle, MIA-602, or MIA-690 (5 μg/d)
(Upper). The graph shows the tumor growth curves. Results are mean ± SEM.
***P < 0.001 vs. vehicle; n = 15 in each group. (B) Tumor weight in mice treated
with either vehicle or GHRH antagonists. Results are mean ± SEM. ***P < 0.001
vs. vehicle; n = 15. (C) IGF-I levels measured in tumors by ELISA. Results are
mean ± SEM. *P < 0.05 vs. vehicle; n = 6. (D) VEGFmRNA assessed by real-time
PCR and normalized to 18S rRNA. Results, expressed as fold change of vehicle,
are mean ± SEM. **P < 0.01 and ***P < 0.001 vs. vehicle; n = 10.
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(Sigma-Aldrich) and 5-bromodeoxyuridine (BrdU) incorporation ELISA kit
(Roche Diagnostic) as described previously (12).
Combination Studies. Drug synergistic effect was performed according to the
Chou-Talalay method of synergy quantitation using CompuSyn software (47).
Using a cell survival assay and computerized software data, CI values were
generated. A CI of 1 indicates an additive effect between two drugs; a CI greater
than 1 indicates antagonism; and a CI less than 1 indicates a synergistic effect.
Caspase-3 Activity. Caspase-3 activity was assessed by Caspase-3 Colorimetric
Assay Kit (BioVision) in cell lysates, according to themanufacturer’s instruction.
Western Blot Analysis. Western blotting was performed as described
previously (9).
RT-PCR and Real-Time PCR. RT-PCR and real-time PCR analyses were performed
as described previously (9, 12).
Tumor Xenografts. MSTO-211H cells (2 × 106) were resuspended in PBS 1×/
matrigel (Matrigel; Corning) solution (ratio 1:1) and s.c. injected in the right
flank of 6- to 8-wk-old NOD/SCID/gamma chain−/− male mice. When tumors
became palpable, mice were injected with MIA-602 or MIA-690 (s.c., 5 μg/d)
or vehicle, for 4 wk. All procedures were performed according to in-
stitutional guidelines in compliance with national (D.L. N.26, 04/03/2014) and
international law and policies (new directive 2010/63/EU). All mice were bred
at the Animal Facility of the Molecular Biotechnology Center (Turin, Italy),
recognized and approved by the Italian Ministry of Health (protocol #52/
2018-PR).
ACKNOWLEDGMENTS. We thank Dr. Giorgio Scagliotti for helpful criticisms
and the Neuroscience Institute of Turin. This work was supported by the
University of Turin Grant Ex-60% 2017 (to R.G.), the Italian Ministry of
Health Grant 2015ZKHFTA_008 (to E.G.), the Italian Association for Cancer
Research Grant IG15232 (to C.R.), and an Institut Biochimique SA (IBSA)
Foundation 2015 fellowship (I.G.). Work in the A.V.S. laboratory was sup-
ported by the Medical Research Service of the Department of Veterans Af-
fairs and by the University of Miami Miller School of Medicine.
1. Mutti L, et al. (2018) Scientific advances and new frontiers in mesothelioma thera-
peutics. J Thorac Oncol 13:1269–1283.
2. Bibby AC, et al. (2016) Malignant pleural mesothelioma: An update on investigation,
diagnosis and treatment. Eur Respir Rev 25:472–486.
3. Husain AN, et al. (2018) Guidelines for pathologic diagnosis of malignant mesothe-
lioma 2017 update of the consensus statement from the International Mesothelioma
Interest Group. Arch Pathol Lab Med 142:89–108.
4. Sekido Y (2013) Molecular pathogenesis of malignant mesothelioma. Carcinogenesis
34:1413–1419.
5. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV (2011) Growth hormone-
releasing hormone: Not only a neurohormone. Trends Endocrinol Metab 22:311–317.
6. Barabutis N, Schally AV (2010) Growth hormone-releasing hormone: Extrapituitary
effects in physiology and pathology. Cell Cycle 9:4110–4116.
7. Granata R (2016) Peripheral activities of growth hormone-releasing hormone.
J Endocrinol Invest 39:721–727.
8. Kanashiro-Takeuchi RM, et al. (2010) Cardioprotective effects of growth hormone-
releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA 107:
2604–2609.
9. Gesmundo I, et al. (2017) Growth hormone-releasing hormone attenuates cardiac
hypertrophy and improves heart function in pressure overload-induced heart failure.
Proc Natl Acad Sci USA 114:12033–12038.
10. Zhang X, et al. (2015) Beneficial effects of growth hormone-releasing hormone ag-
onists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc Natl Acad
Sci USA 112:13651–13656.
11. Cui T, et al. (2016) Agonistic analogs of growth hormone releasing hormone (GHRH)
promote wound healing by stimulating the proliferation and survival of human
dermal fibroblasts through ERK and AKT pathways. Oncotarget 7:52661–52672.
12. Gallo D, et al. (2015) GH-releasing hormone promotes survival and prevents TNF-
α-induced apoptosis and atrophy in C2C12 myotubes. Endocrinology 156:3239–3252.
13. Granata R, et al. (2009) Growth hormone-releasing hormone promotes survival of
cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat
heart. Cardiovasc Res 83:303–312.
14. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing
hormone: An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci
USA 96:14894–14898.
15. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone-releasing
hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:
33–43.
16. Wang H, et al. (2018) Inhibition of experimental small-cell and non-small-cell lung
cancers by novel antagonists of growth hormone-releasing hormone. Int J Cancer
142:2394–2404.
17. Szereday Z, et al. (2003) Antagonists of growth hormone-releasing hormone inhibit
the proliferation of experimental non-small cell lung carcinoma. Cancer Res 63:
7913–7919.
18. Zarandi M, et al. (2017) Synthesis and structure-activity studies on novel analogs of
human growth hormone releasing hormone (GHRH) with enhanced inhibitory ac-
tivities on tumor growth. Peptides 89:60–70.
19. Gan J, et al. (2016) Growth hormone-releasing hormone receptor antagonists inhibit
human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling. Proc
Natl Acad Sci USA 113:14745–14750.
20. Muñoz-Moreno L, Schally AV, Prieto JC, Carmena MJ, Bajo AM (2018) Growth hor-
mone-releasing hormone receptor antagonists modify molecular machinery in the
progression of prostate cancer. Prostate 78:915–926.
21. Pópulo H, et al. (2017) Inhibitory effects of antagonists of growth hormone-releasing
hormone (GHRH) in thyroid cancer. Horm Cancer 8:314–324.
22. Chu WK, et al. (2016) Antagonists of growth hormone-releasing hormone receptor
induce apoptosis specifically in retinoblastoma cells. Proc Natl Acad Sci USA 113:
14396–14401.
23. Jimenez JJ, et al. (2018) A new approach to the treatment of acute myeloid leukaemia
targeting the receptor for growth hormone-releasing hormone. Br J Haematol 181:
476–485.
24. Klukovits A, et al. (2012) Novel antagonists of growth hormone-releasing hormone
inhibit growth and vascularization of human experimental ovarian cancers. Cancer
118:670–680.
25. Popovics P, Cai R, Sha W, Rick FG, Schally AV (2018) Growth hormone-releasing
hormone antagonists reduce prostatic enlargement and inflammation in carra-
geenan-induced chronic prostatitis. Prostate 78:970–980.
26. Simula L, Nazio F, Campello S (2017) The mitochondrial dynamics in cancer and im-
mune-surveillance. Semin Cancer Biol 47:29–42.
27. Sabharwal SS, Schumacker PT (2014) Mitochondrial ROS in cancer: Initiators, ampli-
fiers or an Achilles’ heel? Nat Rev Cancer 14:709–721.
28. Barabutis N, et al. (2007) Stimulation of proliferation of MCF-7 breast cancer cells by a
transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl
Acad Sci USA 104:5575–5579.
29. Cioce M, et al. (2014) Autocrine CSF-1R signaling drives mesothelioma chemo-
resistance via AKT activation. Cell Death Dis 5:e1167.
30. Rick FG, et al. (2011) Antagonists of growth hormone-releasing hormone (GHRH)
reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci
USA 108:3755–3760.
31. Barabutis N, Schally AV, Siejka A (2018) P53, GHRH, inflammation and cancer.
EBioMedicine 37:557–562.
32. Siejka A, Barabutis N, Schally AV (2012) GHRH antagonist inhibits focal adhesion ki-
nase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in
human lung cancer cells in vitro. Peptides 37:63–68.
33. Wu HM, et al. (2010) Growth hormone-releasing hormone antagonist induces apo-
ptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/
p21. Cancer Lett 298:16–25.
34. Stangelberger A, et al. (2012) Inhibitory effects of antagonists of growth hormone
releasing hormone on experimental prostate cancers are associated with upregula-
tion of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 72:
555–565.
35. Sementino E, et al. (2018) Inactivation of Tp53 and Pten drives rapid development of
pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952–8961.
36. Strizzi L, et al. (2001) Vascular endothelial growth factor is an autocrine growth factor
in human malignant mesothelioma. J Pathol 193:468–475.
37. Tan Y, Sementino E, Chernoff J, Testa JR (2017) Targeting MYC sensitizes malignant
mesothelioma cells to PAK blockage-induced cytotoxicity. Am J Cancer Res 7:
1724–1737.
38. Alì G, et al. (2013) Differential expression of extracellular matrix constituents and cell
adhesion molecules between malignant pleural mesothelioma and mesothelial hy-
perplasia. J Thorac Oncol 8:1389–1395.
39. Schally AV, et al. (2018) Agonists of growth hormone-releasing hormone (GHRH)
inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Proc Natl Acad Sci USA 115:12028–12033.
40. Cui T, Schally AV (2018) Growth hormone-releasing hormone (GHRH) and its agonists
inhibit hepatic and tumoral secretion of IGF-1. Oncotarget 9:28745–28756.
41. Hwang KE, et al. (2015) Pemetrexed induces apoptosis in malignant mesothelioma
and lung cancer cells through activation of reactive oxygen species and inhibition of
sirtuin 1. Oncol Rep 33:2411–2419.
42. Pozsgai E, et al. (2010) The effect of GHRH antagonists on human glioblastomas and
their mechanism of action. Int J Cancer 127:2313–2322.
43. Hohla F, et al. (2009) GHRH antagonist causes DNA damage leading to p21 mediated
cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 8:3149–3156.
44. Hoang CD, et al. (2004) Selective activation of insulin receptor substrate-1 and -2 in
pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer
Res 64:7479–7485.
45. Monica V, et al. (2016) Dasatinib modulates sensitivity to pemetrexed in malignant
pleural mesothelioma cell lines. Oncotarget 7:76577–76589.
46. Kopecka J, et al. (2018) Loss of C/EBP-β LIP drives cisplatin resistance in malignant
pleural mesothelioma. Lung Cancer 120:34–45.
47. Chou TC (2010) Drug combination studies and their synergy quantification using the
Chou-Talalay method. Cancer Res 70:440–446.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1818865116 Villanova et al.
